Here we report the discovery of truncating mutations of the gene encoding the cohesin subunit STAG2, which regulates sister chromatid cohesion and segregation, in 36% of papillary non-invasive urothelial carcinomas and 16% of invasive urothelial carcinomas of the bladder. Our studies suggest that STAG2 has a role in controlling chromosome number but not the proliferation of bladder cancer cells. These findings identify STAG2 as one of the most commonly mutated genes in bladder cancer.
b r i e f c o m m u n i c a t i o n s
Here we report the discovery of truncating mutations of the gene encoding the cohesin subunit STAG2, which regulates sister chromatid cohesion and segregation, in 36% of papillary non-invasive urothelial carcinomas and 16% of invasive urothelial carcinomas of the bladder. Our studies suggest that STAG2 has a role in controlling chromosome number but not the proliferation of bladder cancer cells. These findings identify STAG2 as one of the most commonly mutated genes in bladder cancer.
Inactivating mutations of the cohesin complex gene STAG2 have recently been identified in human cancer and were demonstrated to cause chromosome segregation defects and aneuploidy [1] [2] [3] . To identify additional tumor types with inactivation of the STAG2 gene, we screened 2,214 human tumors by immunohistochemistry using a monoclonal antibody to STAG2 that binds at the C terminus of the protein. As the STAG2 gene is on the X chromosome, complete genetic inactivation of STAG2 requires only a single mutational event. Virtually all tumor-derived STAG2 mutations discovered so far are truncating (for example, nonsense, frameshift or splice site) and lead to absence of the C-terminal epitope and, therefore, loss of expression as detected by immunohistochemistry with the monoclonal antibody 1 . STAG2 was robustly expressed specifically in the nucleus in all non-neoplastic tissues studied (examples shown in Supplementary Figs. 1 and 2) .
We discovered that 52 of 295 urothelial carcinomas of the bladder (18%) had complete loss of STAG2 expression ( Supplementary Fig. 3 and Supplementary Table 1 ). Occasional loss of STAG2 expression was also found in several other tumor types ( Supplementary  Figs. 4-6 ). Urothelial carcinomas that had negative staining for STAG2 included tumors with a wide range of stages and grades, from low-grade, non-invasive papillary tumors to high-grade, muscleinvasive tumors. In each case with loss of STAG2 expression, non-neoplastic stroma and endothelial cells retained expression, demonstrating the somatic nature of STAG2 loss in these tumors. STAG2-negative bladder tumors stained positively with antibodies to the constitutively expressed nuclear protein Ini-1, demonstrating intact immunoreactivity for other nuclear antigens ( Supplementary  Fig. 7 ). In the vast majority of cases, all tumor cells were negative for STAG2 expression; however, in a small number of cases (2/52), there was evidence of mosaicism (intratumoral heterogeneity), with some regions of the tumor retaining expression of STAG2 ( Supplementary  Fig. 8 ). Whereas tumors with complete loss of STAG2 suggest that inactivation occurred as an early, initiating event in these cases, the small number of mosaic tumors suggests that STAG2 can occasionally be inactivated during the early progression stage of urothelial tumorigenesis.
To determine the mechanism underlying the loss of STAG2 expression, we used Sanger sequencing to analyze the STAG2 gene in genomic DNA purified from an independent cohort of 111 primary urothelial carcinomas of various grades and stages (clinicopathological characteristics of the tumors are given in Supplementary Table 2) . We identified 25 mutations in 23 of the cases, with 2 samples each harboring 2 independent mutations ( Fig. 1a and Supplementary Table 3) . Apart from known SNPs, no synonymous mutations were identified. Twenty-one of the 25 mutations resulted in premature truncation of the encoded protein, including 5 nonsense, 6 splice-site and 10 frameshift mutations (Supplementary Fig. 9 ). All mutations were shown to be somatic in samples with matched constitutional DNA (8 samples; Supplementary Table 3) . Mutations were identified in 9 of 25 (36%) pTa non-invasive papillary carcinomas, 6 of 22 (27%) pT1 superficially invasive carcinomas and 8 of 64 (13%) pT2-pT4 muscle-invasive carcinomas. Tumors with truncating STAG2 mutations were negative for STAG2 expression via immunohistochemistry (examples are shown in Fig. 1b and Supplementary Fig. 10 does not identify the ~15% of STAG2-mutant tumors with missense mutations of the gene (Supplementary Fig. 11 ). Truncating mutations were also observed in 5 of 32 urothelial carcinoma cell lines (Supplementary Fig. 12 ). Tumors and cell lines with STAG2 mutations frequently had concurrent p53 overexpression or mutation ( Supplementary Fig. 13 and Supplementary Table 3) .
Next, we performed molecular cytogenetic analysis on 12 primary urothelial carcinomas with STAG2 mutations and 12 stage-matched tumors with wild-type STAG2. Genomic DNA was interrogated using Affymetrix CytoScan HD Arrays, and chromosomal gains and losses were scored for each sample (Supplementary Figs. 14 and 15 and Supplementary Table 4 ). Nine of the 12 STAG2-mutant tumors studied had overt aneuploidy, with up to 35 clonal chromosomal aberrations in a single tumor, whereas 3 tumors with STAG2 mutations did not contain detectable chromosomal aberrations. Ten of the 12 tumors with wild-type STAG2 also contained chromosomal copy number aberrations, demonstrating that there are other pathways whose perturbation also leads to aneuploidy in bladder cancer.
We then constructed a STAG2-expressing lentivirus and infected UM-UC-3, UM-UC-14 and VM-CUB-3 cells, three urothelial carcinoma cell lines with truncating mutations of STAG2 ( Fig. 2a and Supplementary Fig. 16 ). Ectopic re-expression of STAG2 had no adverse effect on cellular proliferation or in vivo growth when cells were injected into mice as subcutaneous xenografts ( Fig. 2b and Supplementary Fig. 16 ). Ectopic re-expression of STAG2 did not overtly reduce the degree of aneuploidy ( Supplementary Fig. 17 ), perhaps because, once aneuploidy is established, it is thought to be largely self-sustaining. In contrast, depletion of wild-type STAG2 via lentivirally expressed short hairpin RNA (shRNA) led to a distinct alteration in the modal chromosome number of RT4 urothelial carcinoma cells (Fig. 2c,d and Supplementary Fig. 18 ). Taken together, these functional experiments provide support for the hypothesis that STAG2 may have a role in controlling chromosomal stability but not in the proliferation of bladder cancer cells.
We next determined the status of STAG2 expression in a panel of 34 papillary non-muscle-invasive urothelial carcinomas treated by transurethral resection with a median follow-up of 54 months (clinicopathological features of these tumors are given in Supplementary  Table 5 ). In this cohort, loss of STAG2 expression was significantly associated with increased disease-free survival (P = 0.05; Supplementary Fig. 19 ). Only 1 of 8 of the STAG2-deficient carcinomas (12%) recurred (as a non-invasive carcinoma), whereas 15 of 26 of the STAG2-expressing carcinomas (58%) recurred (2 recurred as invasive carcinomas, and 4 metastasized).
We then determined the status of STAG2 expression in a clinically annotated panel of 349 invasive urothelial carcinomas treated by radical cystectomy with a median follow-up of 130 months (clinicopathological features of these tumors are given in Supplementary  Table 6 ). In these invasive tumors, loss of STAG2 expression was significantly associated (P = 0.03) with increased frequency of metastasis to the lymph node. Fig. 20) . Loss of STAG2 expression was also associated with increased risk of disease recurrence (P = 0.04) and with cancer-specific mortality (P = 0.04; Supplementary Fig. 21 ). The biological basis for the different effects of STAG2 expression on the clinical outcomes of non-muscle-invasive papillary carcinomas versus muscle-invasive carcinomas is currently unknown. Bladder cancer is the fifth most common human malignancy in the United States, with approximately 74,000 new cases diagnosed each year and approximately 15,000 deaths 4 . Bladder cancer is thought to arise via two different pathways-from papillary lesions that frequently recur but only 15-20% of which progress to muscle invasion and from flat dysplastic lesions (carcinoma in situ) that directly progress to muscle invasion without a papillary precursor lesion. The majority of bladder cancers are papillary non-invasive tumors; clinical management of these tumors poses a serious dilemma because it is not currently possible to prospectively determine whether a tumor will recur or progress to invasion.
It is notable that STAG2 mutations occur and are most common in early-stage bladder cancers, including non-invasive papillary carcinomas. As such, we suggest that STAG2 mutation is an early event in bladder tumorigenesis. Furthermore, our data suggest that the major mechanism for STAG2 inactivation in bladder cancer is somatic truncating (~85%) and missense (~15%) mutations (rather than homozygous deletion or promoter hypermethylation), as all STAG2-deficient cell lines and primary tumors studied harbored truncating mutations in the gene.
Whether mutations in STAG2 are a direct cause of aneuploidy in human cancer is currently a source of controversy because a subset of STAG2-deficient acute myeloid leukemias and urothelial carcinomas appear to be diploid (refs. 2,5 and Supplementary Table 4) . Despite these surprising observations, there are several lines of evidence supporting a direct role for STAG2 inactivation in aneuploidy in cancer. In yeast, mutation of cohesin complex genes causes aberrant chromosome segregation and aneuploidy 6, 7 . Recently, a mouse harboring genetic inactivation of Stag1, a homolog of Stag2, was generated that has increased aneuploidy due to chromosome segregation defects 8 . Targeted inactivation of STAG2 in HCT116 colon cancer cells and depletion of STAG2 in RT4 bladder cancer cells leads to alterations in modal chromosome number ( ref. 1 and Fig. 2d) . Also, ectopic expression of STAG2 has no adverse effect on cellular proliferation or in vivo growth (Fig. 2b and Supplementary Fig. 16 ), and targeted correction of endogenous mutant STAG2 in two cancer cell lines resulted in no significant change in global gene expression profiles, arguing against a role for STAG2 in controlling signaling pathways, cellular proliferation, apoptosis or other transformationassociated processes 1 .
Finally, this discovery has potentially important clinical applications, as a major problem in the treatment of bladder cancer has been the identification of those 15-20% of papillary tumors that will recur and progress to invasion versus the 80-85% that will not. Here we report that STAG2 is mutationally inactivated in more than one-third of papillary non-invasive bladder tumors and that these tumors with STAG2 loss rarely recur or progress, perhaps explaining the difference in the frequencies of STAG2 inactivation in non-invasive urothelial carcinomas (36%) compared to in invasive urothelial carcinomas (16%). As the immunohistochemical assay for loss of STAG2 expression is robust and routine clinical sequencing of tumors is imminent, the discovery reported here may have near-term implications for the clinical management of patients with bladder cancer.
MeTHOdS
Methods and any associated references are available in the online version of the paper.
Accession codes. Scanned array images and processed data sets have been deposited in the Gene Expression Omnibus (GEO) under accession GSE41581.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINe MeTHOdS
Tumor specimens. Of the 2,214 tumor samples screened by immunohistochemistry and described in Supplementary Table 1, 1,848 were anonymized, well-characterized tumor samples assembled into multitumor blocks each containing 5-50 cases, as described previously 9,10 . The remainder of the 366 samples described in Supplementary Table 1 were from (i) a Ewing sarcoma tumor microarray created from resection specimens at Leiden University Medical Center containing 21 informative cases spotted in triplicate, (ii) ovarian cancer tumor microarray OV1921 from US Biomax containing 76 informative cases spotted in duplicate, (iii) bladder cancer tumor microarray BL1002 from US Biomax containing 37 informative cases spotted in duplicate, (iv) bladder cancer tumor microarray BLC1501 from US Biomax containing 70 informative cases spotted in duplicate, (v) bladder cancer tumor microarray BL1921 from US Biomax containing 79 informative cases spotted in duplicate and (vi) a bladder cancer tumor microarray created from resection specimens at the MD Anderson Cancer Center containing 83 informative cases 11 .
For DNA sequencing, genomic DNA was prepared from snap-frozen, treatment-naive urothelial carcinomas resected at the MD Anderson Cancer Center and the Johns Hopkins University Hospital. The clinicopathological characteristics of these tumors are described in Supplementary Table 2 .
For the outcomes study described in Supplementary Figure 19 , a clinically annotated tumor microarray containing 34 cases of papillary nonmuscle-invasive urothelial carcinoma of the bladder from individuals treated with transurethral resection was assessed for STAG2 status by immunohistochemistry. Creation and validation of this tumor microarray has been described previously 11 .
For the outcomes study described in Supplementary Figure 21 , a clinically annotated tumor microarray created from 349 consecutive individuals treated with radical cystectomy for invasive urothelial carcinoma of the bladder between 1988 and 2003 at a single center was assessed for STAG2 status by immunohistochemistry. Creation and validation of these tumor microarrays has been described previously 12 . No subject received preoperative systemic chemotherapy or radiotherapy, and no subject had known metastatic disease at the time of surgery. Postoperatively, subjects were generally seen at least three times in year 1, semiannually in year 2 and annually thereafter. Diagnostic imaging of the upper tract and chest radiography were performed at least annually or as clinically indicated. Individuals identified as having died of urothelial carcinoma had progressive, disseminated and often symptomatic metastases at death. All specimens were collected from properly consented patients at all participating sites in accordance with the institutional review board-approved study.
Immunohistochemistry.
A mouse monoclonal antibody to STAG2 from Santa Cruz Biotechnology (clone J-12, sc-81852) was used at a dilution of 1:100. A mouse monoclonal antibody to p53 from Dako (clone DO-7, M7001) was used at a 1:25 dilution. Immunostaining was performed in an automated immunostainer (Leica Bond-Max) following heat-induced antigen retrieval for 30 min in high pH epitope retrieval buffer (Bond-Max). Primary antibody was applied for 30 min, and Bond-Max polymer was applied for 15 min. Diaminobenzidine was used as the chromogen, and samples were counterstained with hematoxylin. Samples in which both the tumor and normal cells failed to stain for STAG2 were considered antigenically non-viable and were excluded from the analysis.
DNA sequencing. Individual exons of STAG2 were PCR amplified from genomic DNA using the conditions and primer pairs described by Solomon et al. 1 . PCR products were purified using the Exo/SAP method followed by a Sephadex spin column. Sequencing reactions were performed using BigDye v3.1 (Applied Biosystems) using an M13F primer and were analyzed on an Applied Biosystems 3730xl capillary sequencer. Sequences were analyzed using Mutation Surveyor (SoftGenetics). Traces with putative mutations were reamplified and sequenced from both tumor and matched normal DNA from blood when available.
Protein blots. Primary antibodies used were STAG2 clone J-12 (Santa Cruz Biotechnology, sc-81852) and α-tubulin Ab-2 clone DM1A (Neomarkers). Protein was isolated from 32 human urothelial carcinoma cell lines in RIPA buffer, resolved by SDS-PAGE and immunoblotted following standard biochemical techniques.
Molecular cytogenetics. Genomic DNA purified from 24 snap-frozen primary urothelial carcinomas was interrogated with Affymetrix CytoScan HD Arrays according to the manufacturer's instructions. Scanned array images and processed data sets have been deposited in GEO (data set GSE41581). CEL files were generated from scanned array image files by Affymetrix GeneChip Command Console software and were imported into Affymetrix Chromosome Analysis Suite v1.2.2 software. Copy number data files (CYCHP files) were generated using ChAS Analysis Files for CytoScan HD Array version NA32.1 (hg19) as a reference.
STAG2 lentiviral expression and shRNA depletion. To create a STAG2-expressing lentivirus, human STAG2 cDNA corresponding to CCDS14607 was synthesized (Genscript), cloned into the lentiviral expression vector pLJM1 (Addgene) and packaged by cotransfection of 293T cells (ATCC) with lentiviral helper plasmids pHR′CMV8.2∆R and pCMV-VSV-G as previously described 13 . Virus-containing conditioned medium was harvested 48 h after transfection, filtered and used to infect recipient cells in the presence of 8 µg/ml polybrene. Infected cells were selected with 2 µg/ml puromycin until all mock-infected cells were dead and were then maintained in puromycin. Identification and validation of lentiviral STAG2 shRNA constructs have been described previously 5 .
CellTiter-Glo proliferation assays. Proliferation of pooled clones of STAG2-mutant urothelial cancer cells infected with empty lentiviral vector or with lentiviral vector expressing STAG2 was performed using the CellTiter-Glo Luminescent Cell Proliferation Assay (Promega) according to the manufacturer's instructions.
Subcutaneous xenograft growth assays. Three million cells from pooled clones of UM-UC-3 cells infected with either empty lentiviral vector or with lentiviral vector expressing STAG2, after puromycin selection, were injected subcutaneously into the flanks of 5-to 6-week-old female athymic mice (nu/nu genotype, BALB/c background; Simonsen Laboratories; n = 10). Tumor volume was measured three times weekly starting on day 13 after injection. Mice were housed and fed under aseptic conditions, and all animal research was approved by the University of California, San Francisco Institutional Animal Care and Use Committee.
